Back to News
Market Impact: 0.25
Johnson & Johnson Presents New Data Validating ICOTYDE In Treatment Of Psoriasis
Source: Nasdaq
Healthcare & BiotechProduct Launches
Johnson & Johnson released new Phase 3 ICONIC-TOTAL study results for ICOTYDE in high-impact plaque psoriasis sites. The data were presented at the 2026 European Academy of Dermatology and Venereology Congress, representing a potentially supportive clinical-development update, although the article excerpt provides no efficacy or safety figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
JNJ0.65
More News
- Your health insurance premiums may take a big jump in 2027 — here's why
- Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals
- Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
- Meta wants you to build your own Muse gadget
- Rivian tops Q3 delivery expectations, reconfirms 2026 guidance
- iPhone 18 Pro Max can’t call or text on AT&T? Apple will replace it for free